The 2024 National Conference on Drug Regulatory Policies and Regulations was held in Beijing from March 28th to 29th.   Xu Jinghe, a member of the Party Group and Deputy Director of the National Medical Products Administration, attended the meeting and delivered a speech.

　　The meeting pointed out that significant achievements have been made in various aspects of drug regulatory policies and regulations in 2023. The Medical Device Management Law has been put on the agenda, significant progress has been made in the revision of administrative regulations, and more than ten regulatory agencies urgently need supporting regulatory documents to be issued. The legal and regulatory system for drug supervision is becoming more complete. We will comprehensively utilize various means such as assessment and evaluation, policy guidance, etc., actively promote cross regional and cross level drug regulatory collaboration, and strengthen the foundation of the "One Country One Game" drug regulatory system. Promote the combination of supervision and law enforcement, promote the standardized operation of license filing, fully leverage the role of reconsideration litigation supervision, and make administrative law enforcement behavior more standardized. Improve the system and mechanism for linking execution, promote the connection between case investigation and execution discipline, and provide stronger services to ensure the needs of grassroots supervision and law enforcement. Strengthen the construction of the legal popularization system and mechanism, promote the construction of legal publicity and education platforms, and be more conscious of respecting, abiding by, and using the law.
 
The conference deployed key tasks for policy and regulatory work in 2024: firstly, to accelerate the revision of important legal regulations and continuously improve the legal and regulatory system for drug supervision; Secondly, we need to improve and strengthen policy research work, actively promote collaboration between the upper and lower levels of the drug regulatory system; Thirdly, we need to deepen the implementation of various administrative behavior norms and requirements, and continuously improve the quality and effectiveness of drug supervision and law enforcement; Fourth, we need to strengthen internal and hierarchical supervision, fully implement the requirements of law enforcement supervision; We must continue to deepen the publicity and education of drug rule of law, comprehensively improve the systematic and precise nature of legal education; Six, we need to strengthen the construction of the drug regulatory policy and regulatory team, and create a high-quality team that is particularly capable of fighting.
At the meeting, officials from the drug regulatory bureaus of five provinces (regions, cities) including Beijing, Hebei, Shanghai, Jiangxi, and Guangxi gave exchange speeches. The main person in charge of the Policy and Regulations Department of the National Medical Products Administration has made specific arrangements for the key work in 2024.
Personnel from the Ministry of Justice and the State Administration for Market Regulation, responsible persons and regulatory department heads of drug regulatory bureaus in various provinces (regions, cities) and Xinjiang Production and Construction Corps, heads of various departments and directly affiliated units of the National Medical Products Administration, legal advisors and public lawyers of the National Medical Products Administration, legal publicity and education bases for drugs in Beijing, and leaders of the China Medical Products Regulatory Research Association, Shanghai Food and Drug Safety Research Association, and the Drug Regulatory Legal Research Center of China University of Political Science and Law attended the meeting.